JUNSNasdaqPharmaceutical PreparationsFiscal year ends December 31
JUPITER NEUROSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$2.75−0.15 (-5.34%)
Close on Oct 19, 2026
- Market cap
- $1.53M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Jupiter Neurosciences's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Marshall Hayward | 4,015,176 | – | 13D (active) | Nov 8, 2024 |
| Claes Wahlestedt | 3,333,816 | 10.90% | 13D (active) | Nov 8, 2024 |
| Shaun Brothers | 2,038,971 | 6.70% | 13D (active) | Nov 8, 2024 |
| Alexander Rosén | 1,789,100 | 5.70% | 13D (active) | Nov 8, 2024 |
| PharmAla Biotech Holdings Inc. | 132,867 | 17.30% | 13G (passive) | Aug 20, 2026 |
| Christer Rosén | 13,069,155 | 39.50% | 13D (active) | Nov 8, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marshall A. Hayward | Chief Scientific Officer, Director | 2,995,077 | 388.93% | Jul 13, 2026 |
| Christer Rosen | CEO and Chairman, Director | 11,078,892 | 1438.67% | Jun 4, 2026 |
| Alison D. Silva | President and COO, Director | 112,777 | 14.64% | Jun 4, 2026 |
| Alexander Gustaf Erik Rosen | Chief Administrative Officer | 617,411 | 80.17% | Jul 13, 2026 |
| Saleem Elmasri | Chief Financial Officer | 66,239 | 8.60% | Jun 4, 2026 |
| Andrew Jon Cutler | Director | – | – | Aug 5, 2026 |
| Holger Weis | Director | 96,581 | 12.54% | Jul 13, 2026 |
| Julie B. Kampf | Director | 82,875 | 10.76% | Jul 13, 2026 |
| Nicholas H. Hemmerly | Director | 95,550 | 12.41% | Jul 13, 2026 |
| Tomas Jan Philipson | Director | – | – | Jul 1, 2026 |
| Allison W. Brady | Director | 21,750 | 2.82% | Jun 5, 2026 |
| Claes Robert Wahlestedt | 10% owner | 2,757,353 | 358.06% | Nov 13, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marshall A. Hayward Chief Scientific Officer, Director | Mar 2, 2026 | Option exercise | +225,000 | – | – | 2,995,077 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jul 1, 2025 | Buy | +3,100 | $1.02 | $3.16K | 11,078,892 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jul 1, 2025 | Buy | +500 | $1.01 | $505 | 11,075,792 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jul 1, 2025 | Buy | +250 | $1.03 | $258 | 112,777 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jul 1, 2025 | Buy | +250 | $1.03 | $258 | 112,277 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jul 1, 2025 | Buy | +250 | $1.03 | $258 | 112,527 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 30, 2025 | Buy | +250 | $1.04 | $260 | 111,927 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 30, 2025 | Buy | +250 | $1.03 | $258 | 111,677 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 30, 2025 | Buy | +250 | $1.02 | $255 | 111 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 30, 2025 | Buy | +100 | $1.02 | $102 | 111,177 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 30, 2025 | Buy | +100 | $1.05 | $105 | 112,027 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +1,450 | $1.02 | $1.48K | 11,072,092 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +1,000 | $0.98 | $980 | 11,068,642 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +2,000 | $1.01 | $2.02K | 11,070,642 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +700 | $1.03 | $721 | 11,072,792 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +1,500 | $1.04 | $1.56K | 11,074,292 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +1,000 | $1.05 | $1.05K | 11,075,292 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 27, 2025 | Buy | +250 | $1.05 | $263 | 111,077 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 27, 2025 | Buy | +250 | $1.04 | $260 | 110,827 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 27, 2025 | Buy | +100 | $1.04 | $104 | 110,577 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 27, 2025 | Buy | +250 | $1.00 | $250 | 110,477 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 27, 2025 | Buy | +166 | $1.06 | $176 | 11,067,642 |
| Nicholas H. Hemmerly Director | Jun 2, 2025 | Option exercise | +95,550 | – | – | 95,550 |
| Julie B. Kampf Director | Jun 2, 2025 | Option exercise | +82,875 | – | – | 82,875 |
| Marshall A. Hayward Chief Scientific Officer, Director | Jun 2, 2025 | Option exercise | +399,402 | – | – | 2,770,077 |
| Marshall A. Hayward Chief Scientific Officer, Director | Jun 2, 2025 | Option exercise | +389,793 | – | – | 2,370,675 |
| Alexander Gustaf Erik Rosen Chief Administrative Officer | Jun 2, 2025 | Option exercise | +96,608 | – | – | 617,411 |
| Alexander Gustaf Erik Rosen Chief Administrative Officer | Jun 2, 2025 | Option exercise | +164,553 | – | – | 520,803 |
| Holger Weis Director | Jun 2, 2025 | Option exercise | +85,800 | – | – | 96,581 |
| Saleem Elmasri CFO and Secretary | Jun 2, 2025 | Option exercise | +66,293 | – | – | 66,239 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 2, 2025 | Option exercise | +110,227 | – | – | 110,227 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 2, 2025 | Option exercise | +476,070 | – | – | 11,067,476 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 2, 2025 | Option exercise | +497,396 | – | – | 10,591,406 |
| Allison W. Brady Director | Jan 22, 2025 | Option exercise | +21,750 | – | – | 21,750 |
| Holger Weis Director | Jan 22, 2025 | Option exercise | +10,781 | – | – | 10,781 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.